Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide

被引:14
|
作者
Montagut, C [1 ]
Bosch, F [1 ]
Villela, L [1 ]
Rosiñol, L [1 ]
Bladé, J [1 ]
机构
[1] Univ Barcelona, Hosp Clin, IDIBAPS, ICMHO,Dept Hematol, E-08036 Barcelona, Spain
关键词
multiple myeloma; thalidomide; aminoglycoside; renal failure;
D O I
10.1080/10428190310001638841
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Thalidomide has been proved to play an important role in rescue treatment of patients with refractory/relapsed multiple myeloma (MM). However, thalidomide therapy is associated with numerous side effects, mainly somnolence, constipation, fatigue or peripheral neuropathy. We report three patients diagnosed with MM and treated with thalidomide as salvage therapy who developed severe renal failure when they received aminoglycoside antibiotics. This observation suggests that thalidomide can potentiate nephrotoxicity of aminoglycoside antibiotics in patients with MM.
引用
收藏
页码:1711 / 1712
页数:2
相关论文
共 50 条
  • [1] Thalidomide in patients with multiple myeloma and renal failure
    Fakhouri, F
    Guerraoui, H
    Presne, C
    Peltier, J
    Delarue, R
    Muret, P
    Knebelmann, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) : 96 - 97
  • [2] Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia
    Harris, E
    Behrens, J
    Samson, D
    Rahemtulla, A
    Russell, NH
    Byrne, JL
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) : 160 - 161
  • [3] CHEMOTHERAPY OF THE PATIENTS WITH MULTIPLE MYELOMA AGGRAVATED BY SEVERE RENAL FAILURE
    Rekhtina, I. G.
    Biryukova, L. S.
    Savchenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2010, 55 (06): : 9 - 13
  • [4] THOMBOPROPHYLAXIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE OR THALIDOMIDE
    Palmaro, A.
    Despas, F.
    Lapeyre-Mestre, M.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E65 - E65
  • [5] Treatment for patients with multiple myeloma complicated by renal failure by thalidomide-based regimens
    Seol, Y.
    Chung, J.
    Kwon, B.
    Song, M.
    Choi, Y.
    Shin, H.
    Kim, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure
    Kuzume, Ayumi
    Tabata, Rikako
    Terao, Toshiki
    Tsushima, Takafumi
    Miura, Daisuke
    Narita, Kentaro
    Takeuchi, Masami
    Matsue, Kosei
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : E33 - E36
  • [7] Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure
    Tosi, P
    Zamagni, E
    Cellini, C
    Cangini, D
    Tacchetti, P
    Tura, S
    Baccarani, M
    Cavo, M
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (02) : 98 - 103
  • [8] Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy
    James Wang
    Kyle A. Udd
    Aleksandra Vidisheva
    Regina A. Swift
    Tanya M. Spektor
    Eric Bravin
    Emad Ibrahim
    Jonathan Treisman
    Mohammed Masri
    James R. Berenson
    Supportive Care in Cancer, 2016, 24 : 3105 - 3110
  • [9] Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy
    Wang, James
    Udd, Kyle A.
    Vidisheva, Aleksandra
    Swift, Regina A.
    Spektor, Tanya M.
    Bravin, Eric
    Ibrahim, Emad
    Treisman, Jonathan
    Masri, Mohammed
    Berenson, James R.
    SUPPORTIVE CARE IN CANCER, 2016, 24 (07) : 3105 - 3110
  • [10] Thalidomide induced neuropathy in patients treated for multiple myeloma.
    Caravita, T
    Arciprete, F
    Siniscalchi, A
    Santinelli, S
    Iani, C
    Amadori, S
    BLOOD, 2002, 100 (11) : 385B - 385B